Omnicell, Inc. (NASDAQ:OMCL) Stock Holdings Boosted by Hillsdale Investment Management Inc.

Hillsdale Investment Management Inc. lifted its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 0.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 92,897 shares of the company’s stock after purchasing an additional 420 shares during the period. Hillsdale Investment Management Inc.’s holdings in Omnicell were worth $4,136,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Smartleaf Asset Management LLC raised its position in shares of Omnicell by 51.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 803 shares of the company’s stock worth $35,000 after purchasing an additional 273 shares during the period. Van ECK Associates Corp increased its stake in Omnicell by 47.0% in the 4th quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock worth $44,000 after purchasing an additional 315 shares in the last quarter. First Horizon Advisors Inc. raised its holdings in Omnicell by 36.3% during the 4th quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company’s stock worth $59,000 after buying an additional 355 shares during the period. Redmond Asset Management LLC lifted its stake in Omnicell by 0.3% during the fourth quarter. Redmond Asset Management LLC now owns 121,209 shares of the company’s stock valued at $5,396,000 after buying an additional 371 shares in the last quarter. Finally, KBC Group NV boosted its holdings in shares of Omnicell by 60.8% in the fourth quarter. KBC Group NV now owns 2,057 shares of the company’s stock worth $92,000 after buying an additional 778 shares during the period. Institutional investors own 97.70% of the company’s stock.

Analysts Set New Price Targets

OMCL has been the topic of a number of recent analyst reports. Wells Fargo & Company cut their price target on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Benchmark restated a “buy” rating and issued a $62.00 target price on shares of Omnicell in a report on Tuesday, February 4th. Bank of America decreased their target price on Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a research report on Monday, January 6th. JPMorgan Chase & Co. dropped their price target on Omnicell from $44.00 to $36.00 and set a “neutral” rating on the stock in a research report on Thursday. Finally, StockNews.com upgraded shares of Omnicell from a “hold” rating to a “buy” rating in a research report on Thursday, March 6th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, Omnicell has a consensus rating of “Hold” and a consensus price target of $51.00.

Omnicell Stock Performance

OMCL opened at $33.94 on Friday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37. The company has a market cap of $1.59 billion, a PE ratio of 125.71, a price-to-earnings-growth ratio of 7.53 and a beta of 0.85. The stock has a 50-day moving average of $39.77 and a 200-day moving average of $42.90. Omnicell, Inc. has a 52-week low of $25.12 and a 52-week high of $55.75.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings results on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. As a group, equities research analysts forecast that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.